Keyword Connections

Tyrosine kinase inhibitor

Journals

6

1 European journal of medicinal chemistry

2 Scientific reports

3 journal of molecular graphics & modelling

4 clinical lymphoma, myeloma & leukemia

5 Therapeutic advances in hematology

6 Cardiovascular toxicology

Research Groups

0

No Research Group Connected

Bibliographies

32

1 The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations.

2 Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update.

3 Potential tripeptides against the tyrosine kinase domain of human epidermal growth factor receptor (HER) 2 through computational and kinase assay approaches.

4 egfr protein expression using a specific intracellular domain antibody and pten and clinical outcomes in squamous cell lung cancer patients with egfr-tyrosine kinase inhibitor therapy

5 tyrosine kinase inhibitor induced isolated pericardial effusion

6 Four-Dimensional Echocardiographic Evaluation of Left Ventricular Systolic Functions in Patients with Chronic Myeloid Leukaemia Receiving Tyrosine Kinase Inhibitors.

7 Pathogenic impact of transcript isoform switching in 1,209 cancer samples covering 27 cancer types using an isoform-specific interaction network.

8 Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta-analysis.

9 Quantification of the tyrosine kinase inhibitor erlotinib in human scalp hair by liquid chromatography-tandem mass spectrometry: Pitfalls for clinical application.

10 RIPK2 Dictates Insulin Responses to Tyrosine Kinase Inhibitors in Obese Male Mice

11 Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor

12 checkpoint molecule pd-1-assisted cd8+ t lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors

13 can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies?

14 tyrosine kinase inhibitors in egfr-mutated large-cell neuroendocrine carcinoma of the lung a case report

15 relationship between bim gene polymorphism and therapeutic efficacy in the retreatment of advanced non-small cell lung cancer with tyrosine kinase inhibitor

16 chemotherapy and egfr tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients

17 alkaline phosphatase flare phenomenon following epidermal growth factor receptor-tyrosine kinase inhibitor treatment of non-small cell lung cancer: report of a case and case review

18 importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance

19 Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2

20 severe adverse effects associated with tyrosine kinase inhibitors therapy in chronic myeloid leukaemia – case reports and literature review

21 Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study.

22 application of epidermal growth factor receptor tyrosine kinase inhibitor as the first-line therapy in patients with advanced non-small cell lung cancer

23 the effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human u87 malignant glioblastoma cells

24 increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis

25 alignment independent 3d-qsar, quantum calculations and molecular docking of mer specific tyrosine kinase inhibitors as anticancer drugs

26 tyrosine kinase inhibitors and pregnancy

27 efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in bcr-abl-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation

28 antibacterial and egfr-tyrosine kinase inhibitory activities of polyhydroxylated xanthones from garcinia succifolia

29 outcomes of research biopsies in clinical trials of egfr mutation-positive non-small cell lung cancer patients pretreated with egfr-tyrosine kinase inhibitors

30 tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in cml patients

31 EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.

32 Design of tyrosine kinase inhibitory compounds and anticancer mechanisms of action